Experience the New Features of the Patsnap Bio Sequence Database in September

In the vast sea of patents, pinpointing a target sequence can be daunting. Utilizing the Patsnap patent database, alongside its Bio Database, simplifies this process.

To acquire patent data related to a delineated antibody sequence, the Patsnap Bio Sequence Database is an optimal resource for conducting a systematic search.

Using the Patsnap Bio Sequence Database for bispecific antibody sequence retrieval is recommended.

Research and development (R&D) efforts in biopharmaceuticals are high, cycles are long, and risks are significant. Companies in this industry heavily rely on core technologies, specialized talents, and intellectual property protection. Drug patents' freedom to operate (FTO) is crucial for determining whether drug candidates can be further commercialized.

The progress of R&D efforts in a life-science area of study can greatly affect the likelihood of breakthroughs and advancements. So, how do we analyze the global research and development progress of the sequence we are studying? I recommend that you use the Patsnap Bio Sequence Database to query data and information.

Sequence modification is an important attribute of a sequence, particularly in the field of small nucleic acids. Sequence modifications, including fluorescence labeling, glycosylation, phosphorylation, and others, can enhance the functionality of a sequence, making them highly meaningful. In the Patsnap Bio Sequence Database, you can search for modified sequences.

Is it sufficient to solely search for nucleotide sequences when searching for a specific nucleotide sequence? Certainly not.

Homology is a qualitative concept where we determine whether two sequences are homologous or not. However, the similarity between homologous sequences can be measured using techniques such as sequence alignment. One popular method for aligning sequences is using BLAST.

Patsnap Bio Sequence Database can achieve the retrieval of antibody light and heavy chains, CDR sequence, and any CDR combination.

The Center for Drug Evaluation, NMPA (CDE) shows that the application for the listing of Overland Pharmaceutical's CD19 antibody-drug conjugate (ADC), Loncastuximab, has been accepted. This is also the first China-reported ADC targeting CD19. CD19 is a popular target in the development of antitumor drugs. If Loncastuximab is approved, multiple types of drugs, including monoclonal antibodies, bispecific antibodies, CAR-T cells, and ADCs, will fulfill this target. We take Loncastuximab as an example to retrieve its related biological sequences.

During the course of scientific research and the development process, researchers may often be confronted with unknown functional sequences. The recommended approach, prior to traditional experimental testing, is to explore their potential functionality and applicability by searching for analogous sequences and relevant patent data in established databases.